O'Grady Brendan P. reported grant involving 210,000 derivative units of Nasus Pharma Ltd on Oct 8, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Chief Executive Officer
Chief Executive Officer
Filed Nov 13, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
—Shares × reported price
Shares traded
210,000Share options (right to buy)
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
210,000Direct
Trade date
Oct 8, 2026Grant
Filed
Nov 13, 2026, 7:35 PM ET37-day reporting delay
Accession
0001493152-26-051888Code A · Transaction 401371
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
2 warnings
delayed filingThe filing was reported 37 calendar days after the transaction date.
missing priceThe filing did not provide a usable price per share.

NSRX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
NSRX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 21, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago +16%1w ago +14%1d ago +13%
Returns since7d30d90d180d1y

Footnotes in full

F1: Options to purchase 210,000 ordinary shares of the Issuer, no par value ("Ordinary Shares"), were granted on July 27, 2026, with one-third of such options, representing 70,000 options, vesting on July 27, 2027, and the remaining two-thirds vesting in eight equal quarterly installments of 17,500 options, beginning on October 27, 2027. The foregoing options are part of the reporting person's compensation package as the Chief Executive Officer of the Issuer, which was approved by the Issuer's shareholders on October 8, 2026. F2: Of the 210,000 options reported herein, the first one-third, representing 70,000 options, will be exercisable at $3.50 per Ordinary Share, the second one-third, representing 70,000 options, will be exercisable at $4.25 per Ordinary Share, and the final one-third, representing 70,000 options, will be exercisable at $5.00 per Ordinary Share; provided that the exercise price of an option may not be less than the Fair Market Value of an Ordinary Share, as defined pursuant to the Issuer's 2019 Incentive Option Plan, including, without limitation, the Sub-Plan for U.S. Persons, on the grant date.